Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss.
Publication
, Journal Article
Kumar, N; D'Alessio, DA
Published in: J Clin Endocrinol Metab
July 14, 2022
Recent evidence from clinical trials supports the efficacy and tolerability of glucagon-like peptide 1 (GLP-1) receptor agonists as useful agents for weight loss. Although originally developed as glucose lowering agents for people with type 2 diabetes, progress in research over the last 3 decades has demonstrated that GLP-1 receptor agonists act in the central nervous system to reduce food intake. This minireview summarizes key aspects of GLP-1 biology and the clinical studies supporting the utility of the GLP-1 receptor signaling system as a therapeutic target for weight loss.
Duke Scholars
Published In
J Clin Endocrinol Metab
DOI
EISSN
1945-7197
Publication Date
July 14, 2022
Volume
107
Issue
8
Start / End Page
2148 / 2153
Location
United States
Related Subject Headings
- Weight Loss
- Hypoglycemic Agents
- Humans
- Glucagon-Like Peptide-1 Receptor
- Glucagon-Like Peptide 1
- Endocrinology & Metabolism
- Diabetes Mellitus, Type 2
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kumar, N., & D’Alessio, D. A. (2022). Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss. J Clin Endocrinol Metab, 107(8), 2148–2153. https://doi.org/10.1210/clinem/dgac276
Kumar, Nitya, and David A. D’Alessio. “Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss.” J Clin Endocrinol Metab 107, no. 8 (July 14, 2022): 2148–53. https://doi.org/10.1210/clinem/dgac276.
Kumar N, D’Alessio DA. Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss. J Clin Endocrinol Metab. 2022 Jul 14;107(8):2148–53.
Kumar, Nitya, and David A. D’Alessio. “Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss.” J Clin Endocrinol Metab, vol. 107, no. 8, July 2022, pp. 2148–53. Pubmed, doi:10.1210/clinem/dgac276.
Kumar N, D’Alessio DA. Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss. J Clin Endocrinol Metab. 2022 Jul 14;107(8):2148–2153.
Published In
J Clin Endocrinol Metab
DOI
EISSN
1945-7197
Publication Date
July 14, 2022
Volume
107
Issue
8
Start / End Page
2148 / 2153
Location
United States
Related Subject Headings
- Weight Loss
- Hypoglycemic Agents
- Humans
- Glucagon-Like Peptide-1 Receptor
- Glucagon-Like Peptide 1
- Endocrinology & Metabolism
- Diabetes Mellitus, Type 2
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences